You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLansoprazole
Accession NumberDB00448  (APRD00077)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. It is manufactured by TAP Pharmaceutical Products. Lansoprazole has been marketed for many years and is one of several PPI’s available.

Structure
Thumb
Synonyms
AG 1749
Bamalite
Lansoprazol
Lansoprazole
Lansoprazolum
Lanzol
Lanzopral
Lanzul
Limpidex
Monolitum
Ogastro
Opiren
Prevacid
External Identifiers
  • A 65006
  • AG 1749
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-lansoprazolecapsule (delayed release)15 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-lansoprazolecapsule (delayed release)30 mgoralDominion Pharmacal2014-07-08Not applicableCanada
Lansoprazolecapsule, delayed release15 mg/1oralSTAT Rx USA LLC2009-11-11Not applicableUs
Lansoprazolecapsule (delayed release)30 mgoralDominion PharmacalNot applicableNot applicableCanada
Lansoprazolecapsule, delayed release30 mg/1oralbryant ranch prepack2009-11-11Not applicableUs
Lansoprazolecapsule (delayed release)30 mgoralPharmascience Inc2015-02-11Not applicableCanada
Lansoprazolecapsule, delayed release30 mg/1oralRebel Distributors Corp2009-11-11Not applicableUs
Lansoprazolecapsule (delayed release)30 mgoralPro Doc Limitee2011-06-07Not applicableCanada
Lansoprazolecapsule (delayed release)15 mgoralPharmascience Inc2015-01-13Not applicableCanada
Lansoprazolecapsule, delayed release15 mg/1oralRebel Distributors Corp2009-11-11Not applicableUs
Lansoprazolecapsule (delayed release)30 mgoralSanis Health Inc2010-11-22Not applicableCanada
Lansoprazolecapsule (delayed release)15 mgoralSanis Health Inc2010-11-23Not applicableCanada
Lansoprazolecapsule (delayed release)30 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Lansoprazolecapsule, delayed release30 mg/1oralSTAT Rx USA LLC2009-11-11Not applicableUs
Lansoprazolecapsule (delayed release)15 mgoralSivem Pharmaceuticals Ulc2012-06-11Not applicableCanada
Lansoprazole-15capsule (delayed release)15 mgoralSivem Pharmaceuticals Ulc2014-10-102015-10-13Canada
Lansoprazole-30capsule (delayed release)30 mgoralSivem Pharmaceuticals Ulc2012-06-112015-10-13Canada
Mylan-lansoprazolecapsule (delayed release)15 mgoralMylan Pharmaceuticals Ulc2010-06-18Not applicableCanada
Mylan-lansoprazolecapsule (delayed release)30 mgoralMylan Pharmaceuticals Ulc2010-06-18Not applicableCanada
Ntp-lansoprazolecapsule (delayed release)30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-lansoprazolecapsule (delayed release)15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
PMS-lansoprazolecapsule (delayed release)30 mgoralPharmascience Inc2013-05-15Not applicableCanada
PMS-lansoprazolecapsule (delayed release)15 mgoralPharmascience Inc2013-05-15Not applicableCanada
Prevacidcapsule, delayed release15 mg/1oralTakeda Pharmaceuticals America, Inc.1995-05-10Not applicableUs
Prevacidtablet, orally disintegrating, delayed release30 mg/1oralPhysicians Total Care, Inc.2005-05-17Not applicableUs
Prevacidcapsule, delayed release30 mg/1oralTakeda Pharmaceuticals America, Inc.1995-05-10Not applicableUs
Prevacidcapsule, delayed release30 mg/1oralPhysicians Total Care, Inc.2000-08-30Not applicableUs
Prevacidcapsule, delayed release15 mg/1oralPhysicians Total Care, Inc.2000-11-28Not applicableUs
Prevacidcapsule, delayed release15 mg/1oralbryant ranch prepack1995-05-10Not applicableUs
Prevacidcapsule, delayed release30 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1995-05-10Not applicableUs
Prevacidcapsule, delayed release30 mg/1oralbryant ranch prepack1995-05-10Not applicableUs
Prevacidcapsule, delayed release30 mg/1oralPd Rx Pharmaceuticals, Inc.1995-05-10Not applicableUs
Prevacidcapsule (delayed release)30 mgoralTakeda Pharmaceuticals America Inc1995-12-31Not applicableCanada
Prevacidtablet, orally disintegrating, delayed release30 mg/1oralCardinal Health2002-08-30Not applicableUs
Prevacidcapsule (delayed release)15 mgoralTakeda Pharmaceuticals America Inc1995-12-31Not applicableCanada
Prevacidtablet, orally disintegrating, delayed release15 mg/1oralPhysicians Total Care, Inc.2007-07-11Not applicableUs
Prevacid Fastabtablet (delayed-release)30 mgoralTakeda Pharmaceuticals America Inc2005-12-01Not applicableCanada
Prevacid Fastabtablet (delayed-release)15 mgoralTakeda Pharmaceuticals America Inc2006-11-24Not applicableCanada
Prevacid Solutabtablet, orally disintegrating, delayed release15 mg/1oralTakeda Pharmaceuticals America, Inc.2002-08-30Not applicableUs
Prevacid Solutabtablet, orally disintegrating, delayed release30 mg/1oralRebel Distributors Corp2002-08-30Not applicableUs
Prevacid Solutabtablet, orally disintegrating, delayed release30 mg/1oralTakeda Pharmaceuticals America, Inc.2002-08-30Not applicableUs
Q-lansoprazolecapsule (delayed release)30 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-lansoprazolecapsule (delayed release)15 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-lansoprazolecapsule (delayed release)15 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Ran-lansoprazolecapsule (delayed release)30 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-03-22Not applicableCanada
Riva-lansoprazolecapsule (delayed release)15 mgoralLaboratoire Riva Inc2014-06-12Not applicableCanada
Riva-lansoprazolecapsule (delayed release)30 mgoralLaboratoire Riva Inc2014-06-12Not applicableCanada
Sandoz Lansoprazoletablet30 mgoralSandoz Canada Incorporated2012-07-03Not applicableCanada
Sandoz Lansoprazolecapsule (delayed release)15 mgoralSandoz Canada Incorporated2012-07-03Not applicableCanada
Teva-lansoprazolecapsule (delayed release)30 mgoralTeva Canada Limited2009-11-02Not applicableCanada
Teva-lansoprazolecapsule (delayed release)15 mgoralTeva Canada Limited2009-11-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-lansoprazolecapsule (delayed release)30 mgoralApotex Inc2009-06-03Not applicableCanada
Apo-lansoprazolecapsule (delayed release)15 mgoralApotex Inc2009-06-03Not applicableCanada
Lansoprazolecapsule, delayed release15 mg/1oralTeva Pharmaceuticals USA Inc2009-11-11Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralDIRECT RX2014-01-01Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralDr.Reddy's laboratories Ltd.2010-10-15Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralBreckenridge Pharmaceutical, Inc.2012-12-18Not applicableUs
Lansoprazolecapsule, delayed release pellets15 mg/1oralZydus Pharmaceuticals (USA) Inc.2013-08-23Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWockhardt USA LLC.2012-08-10Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
Lansoprazolecapsule, delayed release pellets30 mg/1oralZydus Pharmaceuticals (USA) Inc.2013-08-23Not applicableUs
Lansoprazolecapsule, delayed release pellets30 mg/1oralMylan Institutional Inc.2009-12-01Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralRebel Distributors Corp2010-10-15Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-21Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralUnit Dose Services2009-11-11Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralRebel Distributors Corp2009-11-11Not applicableUs
Lansoprazolecapsule, delayed release pellets15 mg/1oralDIRECT RX2014-01-01Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralDr.Reddy's laboratories Ltd.2010-10-15Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralAmerican Health Packaging2010-09-15Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralPreferred Pharmaceuticals, Inc.2013-06-04Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralSun Pharma Global FZE2013-09-16Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralAidarex Pharmaceuticals LLC2010-10-15Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralDIRECT RX2014-01-01Not applicableUs
Lansoprazoletablet, orally disintegrating, delayed release30 mg/1oralPhysicians Total Care, Inc.2010-11-30Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralAmerican Health Packaging2010-09-15Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-21Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralPreferred Pharmaceuticals, Inc.2014-05-23Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralSun Pharma Global FZE2013-09-16Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralSandoz Inc2010-04-23Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralREMEDYREPACK INC.2015-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralPhysicians Total Care, Inc.2010-11-17Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralBlue Point Laboratories2013-12-01Not applicableUs
Lansoprazolecapsule, delayed release pellets15 mg/1oralbryant ranch prepack2013-08-23Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralPreferred Pharmaceuticals, Inc.2010-10-15Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralActavis Inc2012-12-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralSandoz Inc2010-04-23Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralAmerican Health Packaging2015-08-15Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralPhysicians Total Care, Inc.2009-11-17Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralBlue Point Laboratories2013-12-01Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralbryant ranch prepack2012-08-07Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralActavis Inc2012-12-18Not applicableUs
Lansoprazolecapsule, delayed release pellets30 mg/1oralMylan Pharmaceuticals Inc.2009-11-10Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralAmerican Health Packaging2015-08-15Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralREMEDYREPACK INC.2013-07-09Not applicableUs
Lansoprazolecapsule, delayed release pellets30 mg/1oralCadila Healthcare Limited2013-08-23Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralProficient Rx LP2010-10-15Not applicableUs
Lansoprazolecapsule, delayed release pellets30 mg/1oralPreferred Pharmaceuticals, Inc.2015-01-01Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralAv Kare, Inc.2013-08-05Not applicableUs
Lansoprazolecapsule, delayed release pellets15 mg/1oralMylan Pharmaceuticals Inc.2009-11-10Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralWockhardt Limited2012-08-10Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralREMEDYREPACK INC.2013-03-262016-04-05Us
Lansoprazolecapsule, delayed release pellets15 mg/1oralCadila Healthcare Limited2013-08-23Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralProficient Rx LP2009-11-11Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralPreferred Pharmaceuticals, Inc.2013-06-04Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralAv Kare, Inc.2013-08-05Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralTeva Pharmaceuticals USA Inc2009-11-11Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWockhardt Limited2012-08-10Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralBreckenridge Pharmaceutical, Inc.2012-12-18Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralWockhardt USA LLC.2012-08-10Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralSun Pharmaceutical Industries Limited2014-12-15Not applicableUs
Lansoprazolecapsule, delayed release30 mg/1oralPreferred Pharmaceuticals Inc.2015-09-11Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Berkley and Jensen Lansoprazolecapsule, delayed release15 mg/1oralBJWC2012-05-22Not applicableUs
Careone Lansoprazolecapsule, delayed release15 mg/1oralAmerican Sales Company2012-05-24Not applicableUs
Dg Health Lansoprazolecapsule, delayed release15 mg/1oralDolgencorp, LLC2012-05-21Not applicableUs
Equaline Lansoprazolecapsule, delayed release15 mg/1oralSupervalu Inc2012-05-21Not applicableUs
Equate Lansoprazole Delayed Releasecapsule, delayed release15 mg/1oralWal Mart Stores Inc2014-05-05Not applicableUs
Exchange Select Lansoprazolecapsule, delayed release15 mg/1oralArmy & Air Force Exchange Service2012-06-11Not applicableUs
Good Neighbor Pharmacy Lansoprazolecapsule, delayed release15 mg/1oralAmerisource Bergen2012-05-31Not applicableUs
Good Sense Lansoprazolecapsule, delayed release15 mg/1oralL. Perrigo Company2012-05-24Not applicableUs
Harris Teeter Acid Reducercapsule, delayed release15 mg/1oralHarris Teeter, LLC2015-03-30Not applicableUs
Health Mart Lansoprazolecapsule, delayed release15 mg/1oralMc Kesson2012-05-21Not applicableUs
Healthy Accents Lansoprazolecapsule, delayed release15 mg/1oralDZA Brands LLC2012-05-18Not applicableUs
Heartburn Relief 24 Hourcapsule, delayed release15 mg/1oralOUR FAMILY (Nash Finch Company)2013-03-27Not applicableUs
Kirkland Signature Lansoprazole Delayed Releasecapsule, delayed release15 mg/1oralCostco Wholesale Company2013-12-17Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralP and L Development of New York Corporation2013-01-15Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWestern Family Foods, Inc.2012-07-24Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralPerrigo New York Inc2012-08-07Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralShopko Stores Operating Co., LLC2013-06-05Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralH E B2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralHy Vee Inc2012-05-21Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralSafeway, Inc.2012-12-31Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralSIMPLY RIGHT (Sam's West, Inc.)2013-03-30Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralRite Aid Corporation2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralGericare Pharmaceuticals2013-04-25Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralKroger Company2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralMeijer Distribution Inc2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralMajor Pharmaceuticals2012-03-29Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralPublix Super Markets Inc2012-08-10Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralDr. Reddy's Laboratories Limited2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralChain Drug Consortium, LLC2012-07-06Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralRugby Laboratories Inc2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWockhardt USA LLC.2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWockhardt Limited2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWalgreen Co2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralBest Choice (Valu Merchandisers Company)2012-04-30Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralCVS Pharmacy2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralThe Kroger Co.2012-09-01Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralFreds Inc2012-12-04Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWal Mart Stores Inc2012-05-18Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralSafeway2014-10-07Not applicableUs
Lansoprazolecapsule, delayed release15 mg/1oralWestern Family Foods Inc2012-05-18Not applicableUs
Lansoprazole Heartburn Relief 24 Hourcapsule, delayed release15 mg/1oralQUALITY CHOICE (Chain Drug Marketing Association)2013-04-30Not applicableUs
Leader Lansoprazolecapsule, delayed release15 mg/1oralCardinal Health2012-05-30Not applicableUs
Members Mark Lansoprazolecapsule, delayed release15 mg/1oralSam's West Inc2015-07-16Not applicableUs
Preferred Plus Lansoprazolecapsule, delayed release15 mg/1oralKinray2014-06-09Not applicableUs
Prevacid 24 Hrcapsule, delayed release15 mg/1oralNovartis Consumer Health, Inc.2009-10-12Not applicableUs
Rugby Heartburn Treatmentcapsule, delayed release15 mg/1oralRugby Laboratories2014-05-05Not applicableUs
Shoprite Lansoprazolecapsule, delayed release15 mg/1oralWakefern Food Corporation2013-06-11Not applicableUs
Signature Care Acid Reducercapsule, delayed release15 mg/1oralSafeway2015-09-27Not applicableUs
Simply Right Lansoprazolecapsule, delayed release15 mg/1oralSam's West Inc2014-05-29Not applicableUs
Smart Sense Acid Reducercapsule, delayed release15 mg/1oralKmart Corporation2012-05-22Not applicableUs
Smart Sense Lansoprazolecapsule, delayed release15 mg/1oralKmart Corporation2015-12-28Not applicableUs
Sunmark Lansoprazolecapsule, delayed release15 mg/1oralMc Kesson2012-05-21Not applicableUs
Topcare Lansoprazolecapsule, delayed release15 mg/1oralTopco Associates LLC2012-09-10Not applicableUs
Up and Up Lansoprazolecapsule, delayed release15 mg/1oralTarget Corporation2012-05-18Not applicableUs
Well At Walgreens Lansoprazolecapsule, delayed release15 mg/1oralWalgreen Company2012-05-18Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AgoptonTakeda
BamaliteNot Available
LansolocCipla Medpro
LanzolCipla
LanzopralPharma Investi
LanzopranRanbaxy
LimpidexSigma-Tau
MonolitumSalvat
OgastTakeda
OgastroAbbott
OpirenAlmirall
Prevacid 24HRNovartis
Prevacid IVNovartis
ProsoganTakeda
TakepronTakeda
UlpaxHormona
ZoprolToprak
ZotonPfizer
Brand mixtures
NameLabellerIngredients
Hp-pacTakeda Pharmaceuticals America Inc
Lansoprazole, Amoxicillin, and ClarithromycinTeva Pharmaceuticals USA Inc
SaltsNot Available
Categories
UNII0K5C5T2QPG
CAS number103577-45-3
WeightAverage: 369.361
Monoisotopic: 369.075882012
Chemical FormulaC16H14F3N3O2S
InChI KeyInChIKey=MJIHNNLFOKEZEW-UHFFFAOYSA-N
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)
IUPAC Name
2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole
SMILES
CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Methylpyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
PharmacodynamicsLansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion. Thus, the plasma elimination half-life is less than two hours, while the acid inhibitory effect lasts more than 24 hours.
Mechanism of actionLansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.
Related Articles
AbsorptionThe absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%.
Volume of distributionNot Available
Protein binding97%
Metabolism

Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation.

SubstrateEnzymesProduct
Lansoprazole
5-HydroxylansoprazoleDetails
Lansoprazole
Lansoprazole sulfoneDetails
Route of eliminationFollowing single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.
Half life1.5 (± 1.0) hours
ClearanceNot Available
ToxicitySymptoms of overdose include abdominal pain, nausea and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Lansoprazole Action PathwayDrug actionSMP00227
Lansoprazole Metabolism PathwayDrug metabolismSMP00614
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4986893 CYP2C19*3A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.7007
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.547
P-glycoprotein inhibitor IInhibitor0.5357
P-glycoprotein inhibitor IINon-inhibitor0.8692
Renal organic cation transporterInhibitor0.5521
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateNon-substrate0.8659
CYP450 3A4 substrateSubstrate0.6771
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8768
Ames testNon AMES toxic0.5858
CarcinogenicityNon-carcinogens0.7944
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8997 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8777
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Matrix laboratories ltd
  • Teva pharmaceuticals usa
  • Takeda pharmaceuticals north america inc
  • Novartis consumer health inc
  • Sandoz inc
Packagers
Dosage forms
FormRouteStrength
Kit; capsule; capsule (sustained-release); tabletoral
Capsule, delayed releaseoral30 mg/1
Capsule, delayed release pelletsoral15 mg/1
Capsule, delayed release pelletsoral30 mg/1
Kit
Capsule (delayed release)oral15 mg
Capsule (delayed release)oral30 mg
Tablet, orally disintegrating, delayed releaseoral15 mg/1
Capsule, delayed releaseoral15 mg/1
Tablet (delayed-release)oral15 mg
Tablet (delayed-release)oral30 mg
Tablet, orally disintegrating, delayed releaseoral30 mg/1
Tabletoral30 mg
Prices
Unit descriptionCostUnit
Prevacid SoluTab 100 15 mg Dispersible Tablet Box620.65USD box
Prevacid NapraPAC 84 15-500 mg Kit Box175.8USD box
Prevpac Miscellaneous32.02USD ea
Prevpac patient pack28.22USD each
Lansoprazole 100% powder27.54USD g
Prevacid iv 30 mg vial27.31USD vial
Prevacid dr 15 mg capsule6.25USD capsule
Prevacid SoluTab 30 mg Dispersible Tablet6.21USD dispersible tablet
Prevacid 15 mg capsule dr6.0USD capsule
Prevacid 30 mg capsule dr6.0USD capsule
Prevacid dr 30 mg capsule5.91USD capsule
Lansoprazole 15 mg Delayed Release Capsule5.9USD capsule
Lansoprazole 30 mg Delayed Release Capsule5.9USD capsule
Prevacid 15 mg solutab5.73USD tablet
Prevacid 30 mg solutab5.73USD tablet
Lansoprazole dr 15 mg capsule5.67USD capsule
Lansoprazole dr 30 mg capsule5.67USD capsule
Prevacid 30 mg Delayed Release Capsule4.45USD capsule
Prevacid 15 mg Delayed Release Capsule4.32USD capsule
Apo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Apo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 15 mg Delayed Release Capsule1.17USD capsule
Novo-Lansoprazole 30 mg Delayed Release Capsule1.17USD capsule
Prevacid 24hr dr 15 mg capsule0.86USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1327010 No1994-02-152011-02-15Canada
CA2419067 No2008-12-232021-08-17Canada
US4628098 No1992-11-102009-11-10Us
US6328994 Yes1999-11-172019-11-17Us
US7396841 Yes2002-02-172022-02-17Us
US7399485 Yes1998-11-262018-11-26Us
US7431942 Yes1999-11-172019-11-17Us
US7875292 Yes1999-11-172019-11-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178-182 °CNot Available
water solubility0.97 mg/LNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.25 mg/mLALOGPS
logP2.84ALOGPS
logP3.03ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.35ChemAxon
pKa (Strongest Basic)4.16ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.87 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity87.61 m3·mol-1ChemAxon
Polarizability34.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-0udi-0090000000-502b719a981f262577baView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0uxr-0890000000-2734547f6dc584ba4877View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-053i-0930000000-94e6e179919ee803d567View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Clarke Slemon, Bob Macel, “Preparation of omeprazole and lansoprazole.” U.S. Patent US5374730, issued December, 1986.

US5374730
General ReferencesNot Available
External Links
ATC CodesA02BC03A02BC53A02BD02A02BD03A02BD07A02BD09A02BD10
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Lansoprazole.
Alendronic acidThe therapeutic efficacy of Alendronate can be decreased when used in combination with Lansoprazole.
AmphetamineLansoprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lansoprazole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Lansoprazole.
BexaroteneThe serum concentration of Lansoprazole can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Lansoprazole can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Lansoprazole.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Lansoprazole.
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Lansoprazole.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Lansoprazole resulting in a loss in efficacy.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Lansoprazole.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Lansoprazole resulting in a loss in efficacy.
DabrafenibThe serum concentration of Lansoprazole can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Lansoprazole.
DeferasiroxThe serum concentration of Lansoprazole can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Lansoprazole.
DexmethylphenidateLansoprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineLansoprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Lansoprazole.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Lansoprazole.
FluconazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fluconazole.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Lansoprazole.
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.
ImatinibLansoprazole may increase the dermatologic adverse activities of Imatinib.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Lansoprazole.
Iron DextranLansoprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Lansoprazole.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Lansoprazole.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Lansoprazole.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Lansoprazole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lansoprazole.
MethylphenidateLansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MitotaneThe serum concentration of Lansoprazole can be decreased when it is combined with Mitotane.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Lansoprazole.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Lansoprazole resulting in a loss in efficacy.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Lansoprazole.
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Lansoprazole.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Lansoprazole.
PhenytoinThe metabolism of Lansoprazole can be increased when combined with Phenytoin.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Lansoprazole.
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Lansoprazole.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Lansoprazole.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Lansoprazole.
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Lansoprazole.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Lansoprazole.
SiltuximabThe serum concentration of Lansoprazole can be decreased when it is combined with Siltuximab.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Lansoprazole.
St. John's WortThe serum concentration of Lansoprazole can be decreased when it is combined with St. John's Wort.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole.
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Lansoprazole.
TipranavirThe serum concentration of Lansoprazole can be decreased when it is combined with Tipranavir.
TocilizumabThe serum concentration of Lansoprazole can be decreased when it is combined with Tocilizumab.
VoriconazoleThe serum concentration of Lansoprazole can be increased when it is combined with Voriconazole.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Lansoprazole.
Zoledronic acidThe therapeutic efficacy of Zoledronate can be decreased when used in combination with Lansoprazole.
Food Interactions
  • Avoid alcohol.
  • Food reduces bioavailabilty, but this has very little clinical impact.
  • Take 30-60 minutes before meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Matheson AJ, Jarvis B: Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001;61(12):1801-33. [PubMed:11693467 ]
  2. Langtry HD, Wilde MI: Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997 Sep;54(3):473-500. [PubMed:9279507 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010 ]
  2. Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T: Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol. 2009 Jun;65(6):593-600. doi: 10.1007/s00228-009-0625-8. Epub 2009 Feb 24. [PubMed:19238367 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 01, 2016 03:05